Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (June 2010)

32 slides from Auxilium Pharmaceuticals's investor presentation, Jun 8, 2010

  1. Slide 1: June 2010

    June 2010 (NASDAQ: AUXL) Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the opportunities to build shareholder value;

  3. Slide 3: Opportunities to Build Shareholder Value

    Opportunities to Build Shareholder Value ® Note: Seeking partners for Transmucosal film product candidates

  4. Slide 4: XIAFLEX transforming treatment

    IAB colagenase clostridium histolyticum TRANSFORMING TREATMENT oc esasr-an5-01 Rconly collagenase clostridium histolyticut (0.9 mg per vial for injection for intralesional use ‘Attention: Dispense the e- Medication Guide to each: sp de

  5. Slide 5: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity

    XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: Approved on February 2, 2010 for Dupuytren’s Contracture in U.S. Promising phase IIb results in Peyronie’s disease • Well-characterized mode of action • Worldwi

  6. Slide 6: Dupuytren's Contracture is Debilitating for Patients

    Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery has been th

  7. Slide 7: Treatment Options Historically Limited to Invasive Surgery

    Treatment Options Historically Limited to Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Needle fasciotomy/ aponeurotomy • Amputation • Non-surgical options > Splinting > Physical therapy > Corticosteroids

  8. Slide 8: XIAFLEX Offers the First Nonsurgical Treatment for Dupuytren's Contracture

    XIAFLEX Offers the First Nonsurgical Treatment for Dupuytren’s Contracture

  9. Slide 9: A Significant Number of Patients Benefited from Treatment with XIAFLEX

    A Significant Number of Dupuytren’s Contracture Patients Benefited from Treatment with XIAFLEX

  10. Slide 10: Early Intervention with XIAFLEX May Be the Most Effective Approach

    Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach Hurst et al. NEJM 2009 N=248 N=125 Keith Denkler, M.D. Plast. Reconstr. Surg., 115802, 2005 Dupuytren’s Fasciectomies in 60 Consecutive Digits using lidocaine with epinepherine and no tournequet

  11. Slide 11: XIAFLEX Was Well-Tolerated in Phase III Studies

    XIAFLEX Was Well-Tolerated in Phase III Studies • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 days across studies • Serious Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of

  12. Slide 12: Contracture Recurrence Affects Patients

    Contracture Recurrence Affects Patients • The earliest reports of recurrence for surgery were seen in 22% of female and 19% of male Dupuytren’s contracture patients at a mean of months following fasciectomy . Additionally, a rate of up to 34% has been reported within the first years following surger

  13. Slide 13: Two Year Recurrence Rate of 19.3% for XIAFLEX

    Two Year Recurrence Rate of 19.3% for XIAFLEX ® in Dupuytren’s Contracture All Joints MP Joints PIP Joints Patients from All Phase III Studies (n=950) 1,568 Patients Enrolled in Extension Study (n=634) 1,065 Patients Successfully Treated and Enrolled in Extension Study (n=474) 619* 449* Joints with

  14. Slide 14: Launch Update Through May 2010

    Launch Update Through May 2010

  15. Slide 15: Key Objectives for U.S. XIAFLEX Launch in 2010

    Key Objectives for U.S. XIAFLEX Launch in 2010 • Position XIAFLEX as a paradigm changing non-surgical treatment alternative for physicians, payers and patients • Achieve high awareness among targeted physicians and diagnosed patients • Get targeted physicians through the sales cycle – from interest

  16. Slide 16: First Commercial Patient Injected

    First Commercial Patient Injected Patient with 50 degree MP cord pre injection Post manipulation – Able to lay hand flat on table Post injection and pre manipulation Individual results may vary. See Hurst et al. NEJM 2009

  17. Slide 17: Targeting the Eligible Patient Population Should Drive Market Development

    We Believe that Targeting the Eligible Patient Population Should Drive Development of the U.S. Market to Its Full Potential 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data Based Projections (BESS database used, Medicare 5% d

  18. Slide 18: XIAFLEX Launch Strategy is Tailored to Customer Needs

    XIAFLEX Launch Strategy is Tailored to Customer Needs • ~ 7,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists • ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists • Medical science liaisons – Key opini

  19. Slide 19: Access to Physicians

    Access to Physicians • Since launch in late March, majority of physicians called upon receptive to meeting with our sales reps • Significant time being spent with office staff – Calls can typically run from 30 minutes to 3 hours • Changing a treatment paradigm takes time

  20. Slide 20: Unique Sales Cycle for Targeted Physicians

    Unique Sales Cycle for Targeted Physicians Physician Interest, Training & Enrollment Successful XIAFLEX XPERIENCE

  21. Slide 21: Changing Treatment Paradigm and Reimbursement Cycle May Drive Adoption

    Changing Treatment Paradigm and Reimbursement Cycle May Drive Physician Adoption Rate Prior to treatment decision Physician must go through: •Awareness •Interest •Training / Enrollment into XIAFLEX XPERIENCE program •Reimbursement education / comfort •Patient Identification / counseling 11 – 21 week

  22. Slide 22: Reimbursement Processes Are New to Target Physicians

    Reimbursement Processes Are New to Target Physicians • Accounts need customized support every step of the way • Miscellaneous J and CPT codes being used; component and bundled approaches are being accepted • C-code for institutional use will be effective July 1, 2010 • CMS has recommended a J-Code f

  23. Slide 23: Over 1,400 physicians and 900 sites enrolled in XIAFLEX XPERIENCE

    Leading Indicators Trending Positively - Over 1,400 physicians and 900 sites have enrolled in XIAFLEX XPERIENCE program

  24. Slide 24: Leading Indicators - Cumulative Call Center Volume

    Leading Indicators Trending Positively - Cumulative Call Center Volume Note: SP = Specialty Pharmacy; IV = Insurance Verification

  25. Slide 25: Leading Indicators - Sites that have ordered XIAFLEX

    Leading Indicators Trending Positively - Sites that have ordered XIAFLEX

  26. Slide 26: Approximately 87% of insured lives have access to XIAFLEX

    Approximately 87% of insured lives have access to XIAFLEX

  27. Slide 27: Out of Pocket Costs In Line With Our Expectations

    Out of Pocket Costs In Line With Our Expectations Source: Data processed by AUXL call center through May 31, 2010 A significant portion of patients paying 20% and above have a secondary insurance, which may cover a portion of this cost % Of Treatment Cost Paid by Patient

  28. Slide 28: Distribution Network is Operating Smoothly

    Distribution Network is Operating Smoothly

  29. Slide 29: We Believe Launch Strategy Is Sound

    We Believe Launch Strategy Is Sound: • Product efficacy and safety are consistent with clinical data • Access to targeted physicians is good. • Usage is characterized by “test driving”, which is typical for paradigm changing treatment • Payers willing to provide access to drug and procedures • All d

  30. Slide 30: Auxilium's Plan to Provide Visibility on XIAFLEX Launch

    Auxilium’s Plan to Provide Visibility on XIAFLEX Launch • We will pre-release Q2 revenues in early July • On Q2 earnings call we will provide revenue guidance for Q3 • We will continue to provide quarterly revenue guidance through 2010

  31. Slide 31: Strategic Corporate Priorities in 2010

    Strategic Corporate Priorities in 2010 • Execute the launch in the U.S. for XIAFLEX in Dupuytren’s contracture; • Support Pfizer in the ongoing regulatory review of the EMA Dupuytren’s submission and prepare for their potential EU approval; • Commence phase III for XIAFLEX in Peyronie’s disease, ass

  32. Slide 32: Opportunities to Build Shareholder Value

    Opportunities to Build Shareholder Value ® ® Note: Seeking partners for Transmucosal film product candidates

Auxilium Pharmaceuticals — Investor Presentation (June 2010) on 6ix